We found that the TRH-high group had a significantly lower IC50 for AML chemotherapeutics, including cytarabine (p = 0.014) and doxorubicin (p = 0.0018) (Figure 5b), which indicated greater sensitivity to chemotherapy. This evidence concerns the gene TRH and acute myeloid leukemia.